Antibody-Antimicrobial Conjugates for Combating Antibiotic Resistance.
Luofeng YuZifang ShangQizhe JinSiew Yin ChanWeilin HongNan LiPeng LiPublished in: Advanced healthcare materials (2022)
As the development of new antibiotics lags far behind the emergence of drug-resistant bacteria, alternative strategies to resolve this dilemma are urgently required. Antibody-drug conjugate is a promising therapeutic platform to delivering cytotoxic payloads precisely to target cells for efficient disease treatment. Antibody-antimicrobial conjugates (AACs) have recently attracted considerable interest from researchers as they can target bacteria in the target sites and improve the effectiveness of drugs (i.e., reduced drug dosage and adverse effects), abating the upsurge of antimicrobial resistance. In this review, the selection and progress of three essential blocks that compose the AACs: antibodies, antimicrobial payloads, and linkers are discussed. The commonly used conjugation strategies and the latest applications of AACs in recent years are also summarized. The challenges and opportunities of this booming technology are also discussed at the end of this review.
Keyphrases
- drug resistant
- antimicrobial resistance
- staphylococcus aureus
- multidrug resistant
- acinetobacter baumannii
- cancer therapy
- induced apoptosis
- randomized controlled trial
- systematic review
- emergency department
- high throughput
- cystic fibrosis
- signaling pathway
- cell proliferation
- oxidative stress
- cell death
- drug induced
- pseudomonas aeruginosa
- electronic health record
- adverse drug